PROGENRA, INC.

Address

271A GREAT VALLEY PKWY
271A GREAT VALLEY PKWY
MALVERN, PA, 19355-

Information

DUNS: 190641816
# of Employees: N/A

Ownership Information

Hubzone Owned: N
Socially and Economically Disadvantaged: N
Woman Owned: N

Award Charts




Award Listing

  1. Ubiquitin pathway inhibitors for treatment of asthma

    Amount: $222,380.00

    DESCRIPTION (provided by applicant): Asthma is a chronic disease with considerable morbidity and no cures. Symptomatic treatment is efficacious but produces significant adverse effects. Thus, improved ...

    SBIRPhase I2014Department of Health and Human Services
  2. Chemical optimization of a novel class of USP7 inhibitor for cancer treatment

    Amount: $224,974.00

    DESCRIPTION (provided by applicant): Many regulatory proteins are themselves tightly controlled by ubiquitin conjugating and deconjugating enzymes, whose dysfunctional forms are implicated in numerous ...

    SBIRPhase I2014Department of Health and Human Services
  3. Ubiquitin based therapy of aggressive cancer cell populations

    Amount: $224,768.00

    DESCRIPTION (provided by applicant): The degradation of most cellular proteins is regulated by coordinated addition and removal of ubiquitin by families of ubiquitin E3 ligases and deubiquitylating en ...

    SBIRPhase I2014Department of Health and Human Services
  4. Development of selective substrate based inhibitors of ubiquitin isopeptidases

    Amount: $224,379.00

    DESCRIPTION (provided by applicant): The FDA approval of the proteasome inhibitor bortezomib/VELCADE(r) for the treatment of multiple myeloma and other hematological malignancies demonstrates that the ...

    SBIRPhase I2014Department of Health and Human Services
  5. Novel treatment for Huntington???s Disease

    Amount: $224,512.00

    DESCRIPTION (provided by applicant): Because of their degeneracy and selective involvement in most cellular pathways, ubiquitin conjugating and deconjugating enzymes are being explored as therapeutic ...

    SBIRPhase I2014Department of Health and Human Services
  6. Identification of natural products to treat neoplastic disease

    Amount: $342,963.00

    DESCRIPTION (provided by applicant): As in the past, most new FDA-approved drugs for cancer and other indications are derived from natural products or inspired by natural products. Accordingly, it is ...

    SBIRPhase I2012Department of Health and Human Services
  7. Ubiquitin E3 ligase detection by fluorescence resonance transfer

    Amount: $263,031.00

    DESCRIPTION (provided by applicant): Because of its involvement in a broad range of cellular signal transduction and other mechanisms, the ubiquitin pathway is now recognized as a new opportunity for ...

    SBIRPhase I2012Department of Health and Human Services
  8. Novel molecular therapeutics for cystic fibrosis

    Amount: $282,804.00

    DESCRIPTION (provided by applicant): Approximately 70,000 individuals worldwide suffer from the debilitating disease cystic fibrosis (CF), which typically is fatal owing to sepsis in the abnormally v ...

    SBIRPhase I2012Department of Health and Human Services
  9. Selective inhibitors of ubiquitin E3 ligase to treat high cholesterol

    Amount: $296,751.00

    DESCRIPTION (provided by applicant): Hypercholesterolemia is a major factor in cardiovascular disease. In the USA, more than 35 million individuals have high total cholesterol and thus twice the norma ...

    SBIRPhase I2011Department of Health and Human Services
  10. USP34 as a novel target for treatment of idiopathic pulmonary fibrosis

    Amount: $265,823.00

    DESCRIPTION (provided by applicant): Aberrant overactivation of WNT signaling appears to play a major role in Idiopathic Pulmonary Fibrosis (IPF). Inhibitors of overactivated WNT signaling are candida ...

    SBIRPhase I2010Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government